Research Projects

​​​​​​​Ongoing Clinical Trials

​​Completed Clinical Trials

  • “Hypovitaminosis D: A Link between Bone and Fat Fuel Metabolism”. Funded by AUB, USJ and LCNRS. NCT01315366; clinicaltrials.gov. 2011-2015.

    Principle InvestigatorGhada El-Hajj Fuleihan, MD, MPH. 
    Co-investigators
    AUB: Asma ArabiRobert Habib
    HDDF: Rafic Baddoura and Georges Halabi
    RHUH: Samer KabbaniWissam NasreddineMohammad Rawwas

  • CYP2R1 Polymorphisms as Modulators of Circulating 25-Hydroxyvitamin D Levels and of Response to Treatment with Vitamin D. AUB. 2012-2014.

    ​Principle InvestigatorAsma Arabi, MD, MSc. 
    Co-investigatorsGhada El-Hajj Fuleihan, MD, MPH, Nathalie ZgheibRami Mahfoud

  • The Effect of Vitamin D, Atorvastatin, and Fluvastatin on Cardiovascular Disease Risk Factors In Women with Polycystic Ovary Syndrome: A Prospective Randomized Controlled Parallel Three Arm Trial. 2012-2014.

    Principle InvestigatorGhina Ghazeeri
    Co-investigatorsAnwar NassarGhada El-Hajj FuleihanJohny Awwad

  • Vitamin D Status in Mothers and Their Newborns in Lebanon and its Impact on Labor and Neonatal Outcome: A Prospective Cohort Study. 2012-2014.

    Principle InvestigatorFadi Mirza
    Co-investigatorsGhada El-Hajj Fuleihan, Anwar Nassar, Ghina Ghazeeri


  • Phase III (Phase V program), Open-label-Randomized, Referred-Care-Control Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 IU Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women. Merck Sharp & Dohme. 2008-2010. 

    ​Principal Investigator: Asma Arabi, MD, MSc
    ​​Co-investigators: Elie El Haj

  • A multicenter, double –blind, randomized, active controlled, parallel group, non-inferiority study comparing 75 mg Risedronate dosed on two consecutive days monthly with 5 mg daily Risedronate in the treatment of postmenopausal osteoporosis as assessed over 24 months. Aventis. 2005-2007.

    Principle Investigator: Ghada El-Hajj Fuleihan, MD, MPH.
    Co-investigators: Asma Arabi, Joyce Maalouf.

  • Effect of vitamin D replacement on musculoskeletal parameters in healthy school children: a randomized controlled trial. J Clin Endocrinol Metab 2006;91:405-412.

    Principle Investigator: Ghada El-Hajj Fuleihan, MD, MPH.
    Co-investigators: Mona Nabulsi, Joyce Maalouf, Asma Arabi.

  • A randomized, double blind, placebo-controlled, parallel group, multicenter, two years phase III study to determine the efficacy and safety of Risedronate therapy administered 35 mg once a week in Men with osteoporosis. MASTER trial Aventis/ Procter and Gamble. 2003-2006.

    Principle Investigator: Ghada El-Hajj Fuleihan, MD, MPH.
    Co-investigators: Asma Arabi, Joyce Maalouf.

  • Effect of Vitamin D Replacement on Musculoskeletal Parameters in School Children: A Randomized Controlled Trial. Merck Sharp & Dohme. 2001-2002.

    Principal Investigator: Ghada El-Hajj Fuleihan, MD, MPH.
    Co-investigators: Mona Nabulsi, Hala Tamim, Joyce Maalouf, Mariana Salamoun, Hassan Khalife, Mahmoud Choucair, Asma Arabi, and Reinhold Vieth.